查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症免疫療法的全球市場:治療方法的競爭 - 各治療法，癌症，各用戶的免疫癌症治療市場預測:附執行顧問指南(2025年～2029年)
市場調查報告書
商品編碼
1597911

癌症免疫療法的全球市場:治療方法的競爭 - 各治療法，癌症，各用戶的免疫癌症治療市場預測:附執行顧問指南(2025年～2029年)

Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2025 to 2029
出版日期: | 出版商: Howe Sound Research | 英文 262 Pages | 商品交期: 最快1-2個工作天內

價格

癌症治療領域的革命正在進行中。利用人體自然免疫防禦的新療法正在取得前所未有的成功。全球癌症免疫治療市場價值已達數十億美元，並有望大幅成長。對醫療保健產業的影響是巨大的。

本報告提供全球癌症免疫療法市場相關調查，提供市場概要，以及各治療法，癌症，各用戶趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場指南

第2章 簡介和市場定義

  • 癌症免疫療法是什麼
  • 免疫療法- 迫近來的治療方法
  • 市場定義
  • 調查手法
  • 美國的醫療市場與醫藥品支出- 預測

第3章 免疫療法- 免疫技術指南

  • 免疫系統
  • 免疫腫瘤學技術

第4章 產業概要

  • 市場參與企業- 作用及影響

第5章 市場趨勢

  • 成長促進因素
  • 阻礙成長的要素
  • 治療技術開發

第6章 癌症免疫療法的最近的趨勢

第7章 主要企業的簡介

  • AbbVie
  • Achilles Therapeutics
  • Acumen Pharmaceuticals
  • Adagene
  • Adaptimmune Therapeutics
  • Adicet Bio
  • ALX Oncology Holdings
  • Ambrx Biopharma
  • Amgen
  • Apexigen
  • Arcus Biosciences
  • argenx
  • AstraZeneca
  • Atreca
  • Avalo Therapeutics
  • Avid Bioservices
  • Bavarian Nordic
  • BioAtla
  • Biogen Inc.
  • BioNTech
  • Bolt Biotherapeutics
  • Bristol-Myers Squibb
  • Candel Therapeutics
  • Caribou Biosciences
  • Celldex Therapeutics
  • Checkpoint Therapeutics
  • Chinook Therapeutics
  • Corvus Pharmaceuticals
  • Cullinan Oncology
  • Eli Lilly
  • EOM Pharmaceuticals
  • Evaxion Biotech
  • Genenta Science
  • Gilead Sciences
  • Gracell Biotechnologies
  • Greenwich LifeSciences
  • Gritstone bio
  • Harpoon Therapeutics
  • ImmunityBio
  • Immunocore Holdings
  • Immunome
  • IMV Inc
  • Incyte
  • Indaptus Therapeutics
  • Instil Bio
  • Iovance Biotherapeutics
  • Johnson & Johnson
  • Marker Therapeutics
  • Medicenna Therapeutics
  • Merck & Co.
  • Merus
  • Moderna
  • Mustang Bio
  • Nanobiotix
  • Neoleukin Therapeutics
  • Novartis
  • Novavax
  • Oncorus
  • PDS Biotechnology
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
  • Sensei Biotherapeutics
  • Senti Biosciences
  • Surface Oncology
  • Takeda Pharmaceutical
  • TC Biopharm
  • ThermoGenesis Holdings
  • UroGen Pharma
  • Werewolf Therapeutics
  • Xilio Therapeutics
  • Zymeworks

第8章 全球癌症免疫療法市場

  • 全球市場概要，各國
  • 全球市場概要，不同治療
  • 全球市場概要，各癌症
  • 全球市場概要，各用戶

第9章 全球癌症免疫療法市場- 不同治療

  • 單株抗體
  • 細胞激素
  • 疫苗
  • 細胞為基礎
  • 抑制劑/促效劑
  • 其他

第10章 全球癌症免疫療法市場- 癌症

  • 乳癌
  • 大腸癌症
  • 頸椎癌症
  • 肺癌症
  • 前癌症狀態
  • 前列腺癌症
  • 黑色素瘤
  • 血液癌症
  • 其他

第11章 全球癌症免疫療法市場- 各用戶

  • 製藥公司
  • 診所
  • 其他

第12章 附錄

Report Overview:

Are cures for cancer in sight? What is the opportunity in this market? What companies are poised to benefit? Is disruption a possibility? Find out in this comprehensive report.

A revolution in cancer therapy is underway. New therapy based on using the body's natural immune defenses is having unprecedented success. CAR - T Cells? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out to 2027.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

  • 1.1. Situation Analysis
  • 1.2. Guide for Executives and Marketing Staff
  • 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

  • 2.1. What is Cancer Immunotherapy?
  • 2.2. Immunotherapy - the looming cures
  • 2.3. Market Definition
    • 2.3.1. Market Size
    • 2.3.2. Currency
    • 2.3.3. Years
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. U.S. Medical Market and Pharmceutical Spending - Perspective
    • 2.5.1. Global Expenditures for Medicines

3. Immunotherapy - Guide to Immune Technologies

  • 3.1. The Immune System
    • 3.1.1. Innate immune system
      • 3.1.1.1. Surface barriers
      • 3.1.1.2. Inflammation
      • 3.1.1.3. Complement system
      • 3.1.1.4. Cellular barriers
      • 3.1.1.5. Natural killer cells
    • 3.1.2. Adaptive immune system
      • 3.1.2.1. Lymphocytes
      • 3.1.2.2. Killer T cells
      • 3.1.2.3. Helper T cells
      • 3.1.2.4. Gamma delta T cells
      • 3.1.2.5. B lymphocytes and antibodies
    • 3.1.3. Tumor immunology - the immune surveillance system
  • 3.2. Immuno Oncology Technologies
    • 3.2.1. Monoclonal Antibodies
      • 3.2.1.1. Outlook for Monoclonal Antibodies
      • 3.2.1.2. Companies with Monoclonal Antibodies in their Pipeline
    • 3.2.2. Cancer vaccines
      • 3.2.2.1. Outlook for Cancer Vaccines
      • 3.2.2.2. Companies with Cancer Vaccines in their Pipeline
    • 3.2.3. Cytokines
      • 3.2.3.1. Outlook for Cytokines
      • 3.2.3.2. Companies with Cytokines in their Pipeline
    • 3.2.4. Cell Based Therapies
      • 3.2.4.1. Outlook for Cell Based Therapies
      • 3.2.4.2. Companies with Cell Based Therapies in their Pipeline
    • 3.2.5. Inhibitors/Agonists
      • 3.2.5.1. Outlook for Inhibitors/Agonists
      • 3.2.5.2. Companies with Inhibitors/Agonists in their Pipeline
    • 3.2.6. Antibody Drug Conjugates
      • 3.2.6.1. Outlook for Antibody Drug Conjugates
      • 3.2.6.2. Companies with Antibody Drug Conjugates in their Pipeline
    • 3.2.7. Others
      • 3.2.7.1. Outlook for Other Therapeutics
      • 3.2.7.2. Companies with Viral Therapeutics in their Pipeline
      • 3.2.7.3. Companies with Other Therapeutics in their Pipeline

4. Industry Overview

  • 4.1. Market Players - Roles & Impacts
    • 4.1.1. Drug manufacturers - Larger/pharmaceutical
    • 4.1.2. Drug manufacturers - Generic
    • 4.1.3. Contract Research and Manufacturing
    • 4.1.4. In Vitro Diagnostics Industry
    • 4.1.5. Drug Marketing Companies
    • 4.1.6. Biotechnology Companies
    • 4.1.7. Regulatory Bodies

5. Market Trends

  • 5.1. Factors Driving Growth
    • 5.1.1. Outcome potential
    • 5.1.2. Fast tracking
    • 5.1.3. Funding
    • 5.1.4. Technology Environment
    • 5.1.5. Target Solutions
  • 5.2. Factors Limiting Growth
    • 5.2.1. Cost of Treatment
    • 5.2.2. Clinical Trials Role
    • 5.2.3. Combinations
    • 5.2.4. Protocols
  • 5.3. Therapeutic Technology Development
    • 5.3.1. Combinations - Issues and Complexity
    • 5.3.2. Preference for a drug
    • 5.3.3. Problems of Immunity Engineering
    • 5.3.4. The Role of Cost
    • 5.3.5. The Disruption Dynamic
    • 5.3.6. CAR-T Cell Therapy
    • 5.3.7. The Next Five Years

6. Cancer Immunotherapy Recent Developments

  • 6.1. Recent Developments - Importance and How to Use This Section
    • 6.1.1. Importance of These Developments
    • 6.1.2. How to Use This Section
  • 6.2. Merck, buys into new kind of cancer immunotherapy
  • 6.3. Immunotherapy after surgery
  • 6.4. Anti-CTLA-4 nanobody a promising approach
  • 6.5. Continued Success with Immunotherapy in Melanoma
  • 6.6. AC Immune Receives FDA Fast Track Designation
  • 6.7. LTZ Announces Financing
  • 6.8. Immunotherapy for Cancer Overview
  • 6.9. Implantable device shrinks pancreatic tumors
  • 6.10. mRNA Vaccine And Immunotherapy Reduce Melanoma Recurrence
  • 6.11. Towards a Universal Cancer Immunotherapy
  • 6.12. New Strategy May Improve T-Cell Therapy in Solid Tumors
  • 6.13. Immunotherapy linked to increase in Medicare spending
  • 6.14. Immunotherapy Effective with Ovarian Cancer
  • 6.15. Cancer Immunotherapy Granted Fast Track

7. Profiles of Key Immunotherapy Companies

  • 7.1. AbbVie
  • 7.2. Achilles Therapeutics
  • 7.3. Acumen Pharmaceuticals
  • 7.4. Adagene
  • 7.5. Adaptimmune Therapeutics
  • 7.6. Adicet Bio
  • 7.7. ALX Oncology Holdings
  • 7.8. Ambrx Biopharma
  • 7.9. Amgen
  • 7.10. Apexigen
  • 7.11. Arcus Biosciences
  • 7.12. argenx
  • 7.13. AstraZeneca
  • 7.14. Atreca
  • 7.15. Avalo Therapeutics
  • 7.16. Avid Bioservices
  • 7.17. Bavarian Nordic
  • 7.18. BioAtla
  • 7.19. Biogen Inc.
  • 7.20. BioNTech
  • 7.21. Bolt Biotherapeutics
  • 7.22. Bristol-Myers Squibb
  • 7.23. Candel Therapeutics
  • 7.24. Caribou Biosciences
  • 7.25. Celldex Therapeutics
  • 7.26. Checkpoint Therapeutics
  • 7.27. Chinook Therapeutics
  • 7.28. Corvus Pharmaceuticals
  • 7.29. Cullinan Oncology
  • 7.30. Eli Lilly
  • 7.31. EOM Pharmaceuticals
  • 7.32. Evaxion Biotech
  • 7.33. Genenta Science
  • 7.34. Gilead Sciences
  • 7.35. Gracell Biotechnologies
  • 7.36. Greenwich LifeSciences
  • 7.37. Gritstone bio
  • 7.38. Harpoon Therapeutics
  • 7.39. ImmunityBio
  • 7.40. Immunocore Holdings
  • 7.41. Immunome
  • 7.42. IMV Inc
  • 7.43. Incyte
  • 7.44. Indaptus Therapeutics
  • 7.45. Instil Bio
  • 7.46. Iovance Biotherapeutics
  • 7.47. Johnson & Johnson
  • 7.48. Marker Therapeutics
  • 7.49. Medicenna Therapeutics
  • 7.50. Merck & Co.
  • 7.51. Merus
  • 7.52. Moderna
  • 7.53. Mustang Bio
  • 7.54. Nanobiotix
  • 7.55. Neoleukin Therapeutics
  • 7.56. Novartis
  • 7.57. Novavax
  • 7.58. Oncorus
  • 7.59. PDS Biotechnology
  • 7.60. Pfizer
  • 7.61. Regeneron Pharmaceuticals
  • 7.62. Roche
  • 7.63. Sanofi
  • 7.64. Sensei Biotherapeutics
  • 7.65. Senti Biosciences
  • 7.66. Surface Oncology
  • 7.67. Takeda Pharmaceutical
  • 7.68. TC Biopharm
  • 7.69. ThermoGenesis Holdings
  • 7.70. UroGen Pharma
  • 7.71. Werewolf Therapeutics
  • 7.72. Xilio Therapeutics
  • 7.73. Zymeworks

8. The Global Market for Immuno-Oncology Therapeutics

  • 8.1. Global Market Overview by Country
    • 8.1.1. Table - Global Market by Country
    • 8.1.2. Chart - Global Market by Country
  • 8.2. Global Market by Therapy - Overview
    • 8.2.1. Table - Global Market by Therapy
    • 8.2.2. Chart - Global Market by Therapy - Base/Final Year Comparison
    • 8.2.3. Chart - Global Market by Therapy - Base Year
    • 8.2.4. Chart - Global Market by Therapy - End Year
    • 8.2.5. Chart - Global Market by Therapy - Share by Year
    • 8.2.6. Chart - Global Market by Therapy - Segments Growth
  • 8.3. Global Market by Cancer - Overview
    • 8.3.1. Table - Global Market by Cancer
    • 8.3.2. Chart - Global Market by Cancer - Base/Final Year Comparison
    • 8.3.3. Chart - Global Market by Cancer - Base Year
    • 8.3.4. Chart - Global Market by Cancer - End Year
    • 8.3.5. Chart - Global Market by Cancer - Share by Year
    • 8.3.6. Chart - Global Market by Cancer - Segments Growth
  • 8.4. Global Market by Customer - Overview
    • 8.4.1. Table - Global Market by Customer
    • 8.4.2. Chart - Global Market by Customer - Base/Final Year Comparison
    • 8.4.3. Chart - Global Market by Customer - Base Year
    • 8.4.4. Chart - Global Market by Customer - End Year
    • 8.4.5. Chart - Global Market by Customer - Share by Year
    • 8.4.6. Chart - Global Market by Customer - Segments Growth

9. Global Immuno-Oncology Therapy Markets - By Therapy

  • 9.1. MAB
    • 9.1.1. Table MAB - by Country
    • 9.1.2. Chart - MAB Growth
  • 9.2. Cytokine
    • 9.2.1. Table Cytokine - by Country
    • 9.2.2. Chart - Cytokine Growth
  • 9.3. Vaccine
    • 9.3.1. Table Vaccine - by Country
    • 9.3.2. Chart - Vaccine Growth
  • 9.4. Cell Based
    • 9.4.1. Table Cell Based - by Country
    • 9.4.2. Chart - Cell Based Growth
  • 9.5. Inhibitor/Agonist
    • 9.5.1. Table Inhibitor/Agonist - by Country
    • 9.5.2. Chart - Inhibitor/Agonist Growth
  • 9.6. Other IO Therapy
    • 9.6.1. Table Other IO Therapy - by Country
    • 9.6.2. Chart - Other IO Therapy Growth

10. Global Immuno-Oncology Therapeutic Markets - By Cancer

  • 10.1. Breast
    • 10.1.1. Table Breast - by Country
    • 10.1.2. Chart - Breast Growth
  • 10.2. ColoRectal
    • 10.2.1. Table ColoRectal - by Country
    • 10.2.2. Chart - ColoRectal Growth
  • 10.3. Cervical
    • 10.3.1. Table Cervical - by Country
    • 10.3.2. Chart - Cervical Growth
  • 10.4. Lung
    • 10.4.1. Table Lung - by Country
    • 10.4.2. Chart - Lung Growth
  • 10.5. Precancer
    • 10.5.1. Table Precancer - by Country
    • 10.5.2. Chart - Precancer Growth
  • 10.6. Prostate
    • 10.6.1. Table Prostate - by Country
    • 10.6.2. Chart - Prostate Growth
  • 10.7. Melanoma
    • 10.7.1. Table Melanoma - by Country
    • 10.7.2. Chart - Melanoma Growth
  • 10.8. Blood
    • 10.8.1. Table Blood - by Country
    • 10.8.2. Chart - Blood Growth
  • 10.9. Other Cancer
    • 10.9.1. Table Other Cancer - by Country
    • 10.9.2. Chart - Other Cancer Growth

11. Global Immuno-Oncology Therapeutic Markets - By Customer

  • 11.1. Pharma
    • 11.1.1. Table Pharma - by Country
    • 11.1.2. Chart - Pharma Growth
  • 11.2. Clinic
    • 11.2.1. Table Clinic - by Country
    • 11.2.2. Chart - Clinic Growth
  • 11.3. Other Customer
    • 11.3.1. Table Other Customer - by Country
    • 11.3.2. Chart - Other Customer Growth

12. Appendices

  • 12.1. FDA Cancer Drug Approvals by Year
  • 12.2. Clinical Trials Started
  • 12.3. Prevalence of Cancer Treatments

Table of Tables

  • Table 1: List of Cancers by Mortality
  • Table 2: Overview of Innate and Adaptive Immunity
  • Table 3: Approval Rates of Therapeutic Antibodies
  • Table 4: Monoclonal Antibody Companies
  • Table 5: Cancer Vaccine Companies
  • Table 6: Cytokine Companies
  • Table 7: Cell Based Therapy Companies
  • Table 8: Inhibitor/Agonist Companies
  • Table 9: Antibody Drug Conjugate Companies
  • Table 10: Viral Therapeutics Companies
  • Table 11: Other Therapeutics Companies
  • Table 12: Market Players by Type
  • Table 13: Five Factors Driving Growth
  • Table 14: Four Factors Limiting Growth
  • Table 15 - Global Market by Region
  • Table 16: Global Market by Therapy
  • Table 17: Global Market by Cancer
  • Table 18: Global Market by Customer
  • Table 19: MAB by Country
  • Table 20: Cytokine by Country
  • Table 21: Vaccine by Country
  • Table 22: Cell Based by Country
  • Table 23: Inhibitor/Agonist by Country
  • Table 24: Other IO Therapy by Country
  • Table 25: Breast by Country
  • Table 26: ColoRectal by Country
  • Table 27: Cervical by Country
  • Table 28: Lung by Country
  • Table 29: Precancer by Country
  • Table 30: Prostate by Country
  • Table 31: Melanoma by Country
  • Table 32: Blood by Country
  • Table 33: Other Cancer by Country
  • Table 34: Pharma by Country
  • Table 35: Clinic by Country
  • Table 36: Other Customer by Country

Table of Figures

  • Figure 1: Medicine Expenditures Perspective
  • Figure 2: Helper T Cell Roles
  • Figure 3: Antibody Diagram
  • Figure 4: Macrophages attack a Cancer Cell
  • Figure 5: CAR-T Clinical Trials
  • Figure 6: Antibody Drug Conjugate Diagram
  • Figure 7: Growth rates of IO Therapies
  • Figure 8: Global Market Pareto Chart
  • Figure 9: Global Market by Therapy - Base vs. Final
  • Figure 10: Global Market by Therapy Base Year
  • Figure 11: Global Market by Therapy End Year
  • Figure 12: Therapy Share by Year
  • Figure 13: Therapy Segments Growth
  • Figure 14: Global Market by Cancer - Base vs. Final
  • Figure 15: Global Market by Cancer Base Year
  • Figure 16: Global Market by Cancer End Year
  • Figure 17: Cancer Share by Year
  • Figure 18: Cancer Segments Growth
  • Figure 19: Global Market by Customer - Base vs. Final
  • Figure 20: Global Market by Customer Base Year
  • Figure 21: Global Market by Customer End Year
  • Figure 22: Customer Share by Year
  • Figure 23: Customer Segments Growth
  • Figure 24: MAB Growth
  • Figure 25: Cytokine Growth
  • Figure 26: Vaccine Growth
  • Figure 27: Cell Based Growth
  • Figure 28: Inhibitor/Agonist Growth
  • Figure 29: Other IO Therapy Growth
  • Figure 30: Breast Growth
  • Figure 31: ColoRectal Growth
  • Figure 32: Cervical Growth
  • Figure 33: Lung Growth
  • Figure 34: Precancer Growth
  • Figure 35: Prostate Growth
  • Figure 36: Melanoma Growth
  • Figure 37: Blood Growth
  • Figure 38: Other Cancer Growth
  • Figure 39: Pharma Growth
  • Figure 40: Clinic Growth
  • Figure 41: Other Customer Growth
  • Figure 42: FDA Cancer Drug Approvals by Year
  • Figure 43: Clinical Trials for Immunotherapy by Year
  • Figure 44: Pie Chart of Prevalence of Cancer Treatments